Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

HALO – Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.
HALO
$59.02
Name : Halozyme Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $7,272,503,296.00
EPSttm : 3.76
finviz dynamic chart for HALO
Halozyme Therapeutics, Inc.
$59.02
1.58%
$0.95

Float Short %

7.88

Margin Of Safety %

37

Put/Call OI Ratio

0.49

EPS Next Q Diff

0.33

EPS Last/This Y

1.9

EPS This/Next Y

1.48

Price

59.02

Target Price

65.89

Analyst Recom

2.2

Performance Q

-1.68

Relative Volume

0.65

Beta

1.17

Ticker: HALO




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04HALO540.480.3813742
2025-07-07HALO54.210.490.0113740
2025-07-08HALO55.80.420.1315260
2025-07-09HALO56.590.450.1814616
2025-07-10HALO57.630.440.0914665
2025-07-11HALO57.140.440.1814691
2025-07-14HALO57.650.440.0214699
2025-07-15HALO56.610.449.4914669
2025-07-16HALO57.950.440.0514638
2025-07-17HALO57.820.440.1614652
2025-07-18HALO56.450.440.1414762
2025-07-21HALO55.910.460.0113539
2025-07-22HALO57.550.450.0213654
2025-07-23HALO58.590.450.2013728
2025-07-24HALO58.770.450.0613731
2025-07-25HALO58.230.453.3213754
2025-07-28HALO57.740.460.7813859
2025-07-29HALO59.060.460.4113892
2025-07-30HALO60.090.480.8013858
2025-07-31HALO59.950.490.6213995
2025-08-01HALO590.490.5614157
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04HALO54.0031.5- 5.32
2025-07-07HALO54.2431.5- 5.32
2025-07-08HALO55.8031.5- 5.32
2025-07-09HALO56.5831.5- 5.32
2025-07-10HALO57.6331.5- 5.32
2025-07-11HALO57.1531.5- 5.32
2025-07-14HALO57.6531.5- 5.32
2025-07-15HALO56.6031.5- 5.32
2025-07-16HALO58.0331.5- 5.32
2025-07-17HALO57.8131.5- 5.32
2025-07-18HALO56.4631.5- 5.32
2025-07-21HALO55.9031.5- 5.32
2025-07-22HALO57.5231.5- 5.32
2025-07-23HALO58.5631.5- 5.32
2025-07-24HALO58.7731.5- 5.32
2025-07-25HALO58.2431.5- 5.32
2025-07-28HALO57.7635.1- 5.40
2025-07-29HALO59.0535.1- 5.40
2025-07-30HALO60.0835.1- 5.40
2025-07-31HALO59.9735.1- 5.40
2025-08-01HALO59.0235.1- 5.40
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04HALO-7.30-0.669.08
2025-07-07HALO-7.30-0.709.08
2025-07-08HALO-6.66-0.709.08
2025-07-09HALO-6.66-0.709.08
2025-07-10HALO-6.66-0.709.08
2025-07-11HALO-10.36-0.708.35
2025-07-14HALO-10.36-0.628.35
2025-07-15HALO-10.36-0.628.35
2025-07-16HALO-10.36-0.628.35
2025-07-17HALO-10.36-0.628.35
2025-07-18HALO-10.36-0.628.35
2025-07-21HALO-10.36-0.538.35
2025-07-22HALO-10.36-0.538.35
2025-07-23HALO-10.36-0.538.35
2025-07-24HALO-10.36-0.538.35
2025-07-25HALO-10.36-0.537.88
2025-07-28HALO-10.36-4.447.88
2025-07-29HALO-10.36-4.447.88
2025-07-30HALO-10.36-4.447.88
2025-07-31HALO-10.36-4.447.88
2025-08-01HALO-10.36-4.447.88
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

1.11

Avg. EPS Est. Current Quarter

1.2

Avg. EPS Est. Next Quarter

1.44

Insider Transactions

-10.36

Institutional Transactions

-4.44

Beta

1.17

Average Sales Estimate Current Quarter

282

Average Sales Estimate Next Quarter

330

Fair Value

80.69

Quality Score

97

Growth Score

96

Sentiment Score

81

Actual DrawDown %

16.3

Max Drawdown 5-Year %

-49.1

Target Price

65.89

P/E

15.66

Forward P/E

8.01

PEG

0.54

P/S

6.71

P/B

15.07

P/Free Cash Flow

14.67

EPS

3.77

Average EPS Est. Cur. Y​

5.4

EPS Next Y. (Est.)

6.88

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

44.76

Relative Volume

0.65

Return on Equity vs Sector %

76.9

Return on Equity vs Industry %

95.6

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.09

EBIT Estimation

Halozyme Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 350
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
stock quote shares HALO – Halozyme Therapeutics, Inc. Stock Price stock today
news today HALO – Halozyme Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch HALO – Halozyme Therapeutics, Inc. yahoo finance google finance
stock history HALO – Halozyme Therapeutics, Inc. invest stock market
stock prices HALO premarket after hours
ticker HALO fair value insiders trading